Anti-IL-17A mAb has the potential to disrupt the negative feedback loop of IL-17A in the hypothalamus and impact lipogenesis in surrounding adipose tissue, consequently affecting body weight in psoriasis patients. This evidence concerns the gene IL17A and psoriasis.